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In advanced ovarian cancer, response to combination chemo-
therapy may be as high as 70%, but the majority of patients will
eventually suffer from recurrent disease. Drug resistance prior to
or during the treatment of cancer is a major factor limiting the
effectiveness of anticancer agents. The resistance mechanisms in
ovarian cancer identified thus far can be divided into three groups:
decreased drug accumulation, increased DNA repair, and
enhanced detoxification (Johnson et al, 1993). It is difficult to
determine the contribution of each of these factors to the outcome
of chemotherapy. Human ovarian cancer xenografts might be
useful in the elucidation of mechanisms, not only in tumour cells
but also at the tissue level, that are associated with drug resistance
in vivo.
Glutathione and glutathione-dependent enzymes have been
shown to be involved in the detoxification of cisplatin and alkyl-
ating agents, which are both well-known drugs for the treatment of
ovarian cancer (Schröder et al, 1996). The importance of this
detoxification system has been investigated earlier by our group in
a panel of 15 human ovarian cancer xenografts (Kolfschoten et al,
2000). A relation between glutathione or the activity of the
enzyme glutathione S-transferase and the sensitivity to the anti-
cancer drugs could not be established. This observation confirms
clinical findings that suggest that the glutathione detoxification
system alone does not play a major role in primary drug resistance
in ovarian cancer (Ghazal-Aswad et al, 1996).
Cisplatin conjugated to glutathione can be extruded from the
cell by the ATP-dependent glutathione S-conjugate export pump
(GS-X) (Ishikawa and Ali-Osman, 1993). The GS-X pump
appeared to be functionally related to the multidrug resistance-
associated protein (MRP) (Ishikawa et al, 1995). MRP1-trans-
fected cells, however, were not cross-resistant against cisplatin
(Cole et al, 1994). Moreover, in cisplatin-resistant cells overex-
pression of MRP1 was not evident (Kool et al, 1997). These results
indicate that the term GS-X pump might be inappropiate for the
description of the function of MRP1. MRP1-overexpressing cells
generally show resistance against, for example, anthracyclines,
Vinca alkaloids and epipodophyllotoxins (Loe et al, 1996).
For anthracyclines and multiple other hydrophobic natural prod-
ucts it is known that enhanced cellular drug efflux will occur in the
presence of the ATP-dependent export pump P170-glycoprotein
(Pgp) encoded by the MDR1 gene (Roninson, 1992). Both Pgp and
MRP1 belong to the ATP-binding cassette (ABC) superfamily of
transmembrane transport proteins inducing multidrug resistance.
Pharmacological characterization has revealed that the presence of
MRP is related to a lower degree of resistance than the presence of
Pgp in vitro, i.e. against doxorubicin (Lautier et al, 1996).
More recently, the 110 kD lung resistance protein (LRP) has
been discovered which is not a member of the ABC-superfamily.
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Summary Multidrug resistance (MDR) and more specifically the expression of P-glycoprotein (Pgp) have been studied extensively in vitro.
Unfortunately, it appears that the predictive value of MDR recognized in vitro is mostly an incorrect measure to determine the responsiveness
of a particular tumour in the clinic. This misunderstood or overvalued role of MDR might explain the failure of strategies to reverse Pgp
function by the use of modulators in solid tumours. To obtain more insight in in vivo drug resistance we investigated a panel of 15 human
ovarian cancer xenografts consisting of the most common histological subtypes known in ovarian cancer patients. The response rate to
cisplatin, cyclophosphamide and doxorubicin in the xenografts resembled the results of phase II trials with these agents in ovarian cancer
patients. This resemblance justifies drug resistance studies in this experimental in vivo human tumour system. We determined the expression
levels of MDR1, MRP1, LRP and topoisomerase IIa mRNA by the RNase protection assay and the presence of MRP1 and LRP proteins by
immunohistochemistry. The S-phase fraction was investigated as a separate parameter by flow cytometry. In none of the 15 ovarian cancer
xenografts was MDR1 expression detectable. The expression levels of MRP1 and LRP were low to moderate and resembled the presence of
the MRP1 and LRP proteins. There was a weak, inverse relationship between the expression levels of LRP and sensitivity to cisplatin and
cyclophosphamide (r = –0.44 and –0.45), but not to doxorubicin. The levels of topoisomerase IIa varied among the xenografts (0.73–2.66)
and failed to correlate with doxorubicin resistance (r = 0.14). The S-phase fraction, however, showed a relation with the sensitivity to cisplatin
(r = 0.66). Among the determinants studied in ovarian cancer in vivo, LRP mRNA and the S-phase fraction were the best predictive factors for
drug response and most specifically for the activity of cisplatin. © 2000 Cancer Research Campaign
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doi: 10.1054/ bjoc.2000.1373, available online at http://www.idealibrary.com on LRP has been identified as the major human vault protein
(Scheffer et al, 1995). Structural studies of vaults have indicated
that these may play a role in cytoplasmic redistribution and the
nucleocytoplasmic transport of various substrates. LRP has been
reported to be a marker for drug resistance in vitro, both for MDR-
related drugs (doxorubicin, vincristine) and for other agents
(cisplatin, carboplatin and melphalan) (Izquierdo et al, 1996).
Anthracyclines induce multiple intracellular effects and, thus,
resistance in tumour cells can be a multifactorial phenomenon. In
addition to the role of Pgp and MRP1 in drug resistance, alter-
ations of the nuclear target enzyme topoisomerase II may be
responsible for resistance against doxorubicin (Nielsen et al,
1996). DNA topoisomerase II is a nuclear protein, which is
involved in replication of DNA. The protein exists in two
isoforms, the 170 kD topoisomerase IIa and the 180 kD IIb form.
Topoisomerase IIa is mainly expressed during the S-phase of the
cell cycle and seems to be the preferred target associated with drug
resistance.
As none of the investigated resistance features appeared to be a
good determinant for tumour response we included a parameter
related to cellular kinetics, the S-phase fraction (SPF). In breast
cancer patients it has been shown that the number of proliferating
cells was a predictive factor for response to neoadjuvant
chemotherapy (Chevillard et al, 1996). The S-phase fraction
reflects the number of replicating cells. In general, cells with repli-
cating DNA are more vulnerable to the toxic effect of anti-cancer
agents.
In our laboratory, we have established a panel of 15 human
ovarian cancer xenografts including various histological subtypes
as can be recognized in the clinic. We have demonstrated earlier
that the xenografts have retained the histological pattern and
antigen expression of the tumour of origin (Molthoff et al, 1991).
The chemosensitivity of the panel to individual drugs reflects the
clinical response rates of similar drugs. Previous collaborative
studies showed that human tumour xenografts are useful to predict
activity of potential anticancer agents in ovarian cancer (Boven et
al, 1992; Langdon et al, 1994). We believe that the panel is rele-
vant for studies on in vivo mechanisms of resistance. In the present
experiments we determined the possible contribution of a number
of drug resistance features, including the expression of the MDR1,
MRP1 and LRP genes, topoisomerase IIa expression and the cell
cycle distribution to the chemosensitivity profile of the panel, i.e.
to cisplatin, cyclophosphamide and doxorubicin.
MATERIALS AND METHODS
Human ovarian cancer xenografts and drug sensitivity
Human ovarian cancer xenografts were grown subcutaneously in
the flank of female athymic nude mice (NMRI/Cpb or Hsd:
Athymic Nude-nu, Harlan, Horst, The Netherlands). The
xenografts vary in histological subtype and volume-doubling time
and apart from Ov.Sh and Ov. Vg have all been described before
(Molthoff et al, 1991) (Table 1). As is typical for human tumour
xenografts we have demonstrated that mouse stroma only consists
of thin layers whereas in the original ovarian tumours large zones
of connective tissue can be detected. In addition, xenograft tissue
usually contained less than 10% lactate dehydrogenase of murine
origin (Molthoff et al, 1991).
Tumour-bearing mice were treated with cisplatin, cyclophos-
phamide and doxorubicin at maximum tolerated doses (MTD).
Cisplatin (Bristol-Myers Squibb, Woerden, The Netherlands) as a
solution of 0.5 mg ml–1 was injected i.v. at a dose of 5 mg kg–1
every week ´ 2. Cyclophosphamide (ASTA, Diemen, The Nether-
lands) dissolved in water 50 mg ml–1 was given i.p. twice with 
a 2-week interval at a dose of 150 mg kg–1. Doxorubicin
(Pharmacia, Woerden, The Netherlands) was dissolved in water at
2 mg ml–1 and was injected i.v. at a dose of 8 mg kg–1 every week ´2.
At these schedules the mice were required to show a reversible
weight-loss of up to 15% as a result of treatment. Drug treatment
was started at the time that the tumours had a mean volume of
approximately 100 mm3 (designated as day 0). Treatment and
control groups consisted of 5–7 mice each. Tumours which failed
to reach a volume of 20 mm3 at the start of treatment were consid-
ered inevaluable. The increase in tumour volume from the start of
treatment (Vo) until the value at any given time (Vt) was calculated
for each tumour and expressed as the relative tumour volume
(Vt:Vo) on the day of measurement. The mean of these values was
used to determine the ratio between treated (T) and control (C)
tumours (T:C ´ 100%). The highest percentage of growth inhibi-
tion within a period of 5 weeks was considered the optimal growth
inhibition. The disappearance of tumours upon treatment for at
least 1 month was defined as complete remission. Growth inhibi-
tion of the tumours was expressed as 100% – (T:C ´ 100%). The
drug was considered to be active when the growth inhibition was
> 50%, very active > 75%, and inactive if inhibition of growth was
≤ 50% (Langdon et al, 1994).
mRNA gene expression
The expression levels of MDR1, MRP1, LRP and topoisomerase
IIa were determined with the RNase protection assay, which was
performed as has been described earlier (Giaccone et al, 1995).
Measurements were carried out in at least three separate tumours
from three different passages per ovarian cancer xenograft. Frozen
tumours were pulverized in a microdismembrator and total RNA
was isolated with TRIzol (Life Technologies, Breda, The
Netherlands). Ten mg of total RNA was hybridized with a specific
[a32P]CTP-labelled RNA probe complementary to the various
mRNAs. Positive controls for MDR1 expression were tumour
tissue of subline 2780AD generated from the human ovarian
cancer cell line A2780 upon continuous exposure to doxorubicin
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Table 1 Human ovarian cancer xenografts: histology and volume-doubling
time
Xenograft Histology Ta
d (± SD)
Ov.Ri(C) moderately differentiated serous 10.2 ± 3.5
FKo moderately differentiated serous 11.2 ± 3.7
Ov.Gl poorly differentiated serous 14.0 ± 5.5
OVCAR-3b poorly differentiated serous 6.2 ± 2.1
Ov.Sh poorly differentiated serous 14.6 ± 4.4
Ov.Pe moderately differentiated mucinous 10.5 ± 2.7
Ov.He moderately differentiated mucinous 10.4 ± 2.9
Ov.Gr moderately differentiated mucinous 14.0 ± 6.7
FMa poorly differentiated mucinous 5.9 ± 2.0
FCo clear cell carcinoma 7.6 ± 3.2
Ov.Vg clear cell carcinoma 8.2 ± 2.9
Ov.Me carcinosarcoma 8.1 ± 1.7
MRI-H-207 undifferentiated 3.0 ± 0.6
A2780b undifferentiated 2.9 ± 1.7
H134b undifferentiated 10.8 ± 2.7
aTd, mean tumour volume-doubling time in days; bestablished from cell line(Hamilton et al, 1984) and the colon cancer cell line COLO320
(Jansen et al, 1995). Tumour tissue of the GLC4/ADR subline,
selected with doxorubicin form the human small cell lung cancer
cell line GLC4 (Zijlstra et al, 1987), was used as a positive control
for MRP1 and LRP expression.
The [a32P]CTP-labelled probe for human MDR1 mRNA was
obtained by transcription of a 301 bp MDR1 cDNA fragment
(positions 3500–3801) with SP6 RNA polymerase (Baas et al,
1990). The [a32P]CTP-labelled probe of MRP1 complementary to
the sequences (nucleotides 240–484) at the 5¢ end of the MRP1
mRNA was transcribed using SP6 RNA polymerase (Zaman et al,
1993). The LRP cDNA sequence (nucleotides 2326–2558),
inserted in Apo I site of pBluescript, was transcribed from EcoR I
linearized DNA with the use of T7 RNA polymerase (Scheffer et
al, 1995). The [a32P]CTP-labelled probe specific for topo IIa was
transcribed from Bgl II-linearized DNA from a Topo IIa-Xba I
fragment (nucleotides 1277–2440) (Giaccone et al, 1995) in
pGEM4 by using SP6 RNA polymerase.
Radiolabelled protected probes were visualized by electro-
phoresis through a denaturing 6% polyacrylamide gel and
followed by autoradiography. In all RNase protection assays a
human g-actin probe was included as a control, for RNA integrity
and recovery. The bands were quantitated by densitometric scan-
ning of autoradiographs and the amount of the specific mRNA
relative to the amount of g-actin was calculated.
Immunohistochemistry
Rat monoclonal antibodies MRPr1 and LMR-5 (Flens et al, 1997)
were used to determine the presence of MRP1 and LRP in the
ovarian cancer xenografts. Tissue of GLC4/ADR cells grown as a
xenograft was included for positive MRPr1 and LMR-5 staining.
Cryostat sections from three separate tumours per xenograft were
cut (8 mm), air-dried overnight and fixed in ice-cold acetone for
10 min. The slides were blocked with normal rabbit serum for
15 min and incubated with MRPr1 (5 mg ml–1) or LMR-5 (5 mg
ml–1) diluted in PBS/BSA for 60 min at room temperature. The
slides were then incubated with a peroxidase-conjugated rabbit
anti-rat immunoglobulin (1:25; Dako, Glostrup, Denmark) for 30
min and bound peroxidase was detected with the aminoethyl
carbazole substrate kit (Zymed, San Francisco, CA, USA). MRPr1
and LMR-5 staining was expressed as negative (–) to strongly
positive (++).
Cell-cycle distribution
The cell cycle was determined in three separate tumours from
three different passages per ovarian cancer xenograft, which were
stored at –70°C. Briefly, the frozen tumours were thawed and
minced with scissors in cold phosphate-buffered saline (PBS). The
cell suspension was filtered through a 160 mm metal mesh,
centrifuged at 1200 rpm for 5 min, fixed in a cold 70% ethanol
solution, and stored at 4°C until flow cytometric analysis.
Cells were treated with RNase A (Sigma Chemical
Co,Zwijndrecht, The Netherlands; 250 mg ml–1 in 0.1% Triton
X-100) for 20 min at room temperature. Thereafter, staining of
cells was performed with propidium iodide (Sigma; final concen-
tration 50 mg ml–1) for 20 min at 4°C in the dark. The stained
samples, filtered through a 50 mm nylon mesh, were analysed with
a fluorescence-activated cell sorter (FACS 420; Becton Dickinson,
Mountain View, CA, USA). From each sample, the green fluores-
cence of 5 ´ 103 viable cells was analysed. The S-phase fraction
was calculated using LYSIS II software (provided by Becton
Dickinson).
Statistics
Linear regression analysis was used to determine a possible rela-
tionship between the sensitivity of the human ovarian cancer
xenografts and the drug-resistance features.
RESULTS
Chemosensitivity
Tumour-bearing nude mice were treated in the defined schedules
with cisplatin, cyclophosphamide and doxorubicin. The sensitivi-
ties of the human ovarian cancer xenografts to these drugs are
summarized in Table 2. Individual patterns of responsiveness to
each of the anticancer agents were found among the different
xenografts. Xenografts FKo, Ov.Gr and H134 showed to be resis-
tant against the drugs tested, xenografts Ov.Pe, Ov.He and FCo
were poorly responsive and Ov.Sh, Ov.Me, MRI-H-207 and
A2780 xenografts were best responsive.
mRNA gene and protein expression
MDR1 mRNA was not detectable in any of the 15 human ovarian
cancer xenografts in multiple experiments (Table 3). RNA derived
from 2780AD and COLO320 xenografts were included as positive
controls, which were indeed strongly positive for MDR1 expres-
sion (relative expression of 30.0 and 4.0, respectively). As the
xenografts of FCo showed a consistent expression of MRP1, LRP
and topoisomerase IIa mRNA, in different passages, these
received the value of 1.00 (Table 3). Expression levels in all
tumours were calculated as a relative value of the respective FCo
xenografts.
The variation of the relative MRP1 mRNA levels among the 15
xenografts was small. The expression was 10-fold lower than that
in the control small cell lung cancer subline GLC4/ADR (relative
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Table 2 Growth inhibition (%) obtained by single agents in human ovarian
cancer xenografts
Xenograft Cisplatina Cyclophosphamidea Doxorubicina
Ov.Ri(C) 77 (++) 57 (+) 68 (+)
FKo 42 (–) 4 (–) 8 (–)
Ov.Gl 77 (++) 57 (+) 59 (+)
OVCAR-3 85 (++) 60 (+) 44 (–)
Ov.Sh 94 (++) 94 (++) 91 (++)
Ov.Pe 37 (–) 62 (+) 54 (+)
Ov.He 30 (–) 10 (–) 66 (+)
Ov.Gr 13 (–) 10 (–) 0 (–)
FMa 75 (+) 64 (+) 53 (+)
FCo 45 (–) 39 (–) 67 (+)
Ov.Vg 57 (+) 66 (+) 37 (–)
Ov.Me 80 (++) 97 (++) 69 (+)
MRI-H-207 CRb (++) CR (++) CR (++)
A2780 54 (+) 88 (++) 81 (++)
H134 23 (–) 10 (–) 41 (–)
agrowth inhibition < 50% –; 50%–75% +; ³ 75% ++; bCR = complete
remissionexpression of 10.7; GLC4 relative expression 0.97). The expres-
sion levels of the MRP1 protein were low to moderate in 50%
of the xenografts as determined by immunohistochemistry. The
control GLC4/ADR xenograft showed strongly positive staining.
Xenografts with high levels of MRP1 mRNA expression also
showed detectable levels of the MRP1 protein, except for FKo
tumours. Apart from FKo, in other drug-resistant xenografts Ov.Gr
and H134, MRP1 staining was also negative. In general, no rela-
tion was present between the expression levels of MRP1 mRNA
and the anti-tumour effects of cisplatin or doxorubicin (r = 0.01
and 0.24, respectively).
Low to moderate levels of LRP mRNA expression were found
among the 15 xenografts. LRP mRNA levels varied between 0.37
in A2780 xenografts and 2.20 in the Ov.Pe xenograft. Expression
of  LRP mRNA in the control GLC4/ADR xenografts was
moderate (1.39), while this was low in GLC4 (0.73). In 50% of the
tumour samples the LRP protein could be detected (Table 3). The
control GLC4/ADR tissue also showed low staining. LRP protein
expression correlated with the expression levels of LRP mRNA.
The drug-resistant xenografts FKo and Ov.Gr and the poorly
responsive xenografts Ov.Pe, Ov.He and FCo showed moderate to
high amounts of LRP protein and moderate levels of LRP mRNA
expression. When the expression levels of LRP were compared
with cisplatin and cyclophosphamide sensitivity, there appeared to
be a weak, inverse relation (r = – 0.44 and –0.45, respectively)
(Figure 1), but this was not the case for doxorubicin (r = – 0.15).
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Table 3 Drug resistance features of 15 human ovarian cancer xenografts
Xenografts MDR1 mRNA MRP1 mRNA MRPr1 LRP mRNA LMR-5 Topo IIa S-phase
(±SEM) staining (±SEM) staining mRNA fraction %
(±SEM) (±SEM)
Ov.Ri(C) n.d.a 1.53 ± 0.32 ±/+ 1.29 ± 0.33 –/± 2.66 ± 0.20 20.5 ± 3.0
FKo n.d. 1.49 ± 0.22 – 1.18 ± 0.18 –/± 1.52 ± 0.11 24.8 ± 5.2
Ov.Gl n.d. 1.11 ± 0.15 – 1.27 ± 0.23 –/± 1.29 ± 0.30 22.7 ± 2.5
OVCAR-3 n.d. 0.60 ± 0.13 + 0.80 – 1.74 ± 0.16 31.2 ± 1.4
Ov.Sh n.d. 0.69 ± 0.18 ± 1.26 ± 0.12 +b 1.33 ± 0.08 24.9 ± 2.0
Ov.Pe n.d. 0.81 ± 0.11 + 2.20 ± 0.20 ++ 1.12 ± 0.06 2.4 ± 0.8
Ov.He n.d. 0.70 ± 0.16 – 2.14 ± 0.27 + 0.73 ± 0.10 16.6 ± 3.9
Ov.Gr n.d. 1.08 ± 0.20 – 1.00 ± 0.12 ±/+b 1.18 ± 0.18 10.7 ± 2.1
FMa n.d. 0.99 ± 0.11 – 0.94 ± 0.10 ±/+ 2.06 ± 0.23 17.5 ± 1.0
FCo n.d. 1.0 + 1.0 +b 1.0 8.8 ± 1.6
Ov.Vg n.d. 1.61 ± 0.31 +/++ 1.24 ± 0.30 – 1.09 ± 0.10 13.3 ± 2.2
Ov.Me n.d. 1.02 ± 0.24 –/± 0.79 ± 0.11 – 1.28 ± 0.15 12.6 ± 0.7
MRI-H-207 n.d. 1.22 ± 0.17 – 0.68 ± 0.18 – 1.64 ± 0.14 39.4 ± 4.7
A2780 n.d. 1.13 ± 0.18 – 0.37 ± 0.07 – 1.91 ± 0.25 23.4 ± 2.7
H134 n.d. 0.97 ± 0.16 – 1.49 ± 0.34 – 1.70 ± 0.23 27.0 ± 2.2
a n.d. = not detectable; bheterogeneous staining
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Figure 1 Relation between LRP expression and the growth inhibition (%)
induced by cisplatin or cyclophosphamide in 15 human ovarian cancer
xenografts. Mice bearing well-established tumours were injected with
cisplatin i.v. at a dose of 5 mg kg–1 every week ´ 2 or were treated with
cyclophosphamide twice i.p. with a 2-week interval at a dose of 150 mg kg–1.
The r value was calculated by linear regression analysis.
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Figure 2 Relation between the S-phase fraction and growth inhibition (%)
induced by cisplatin in human 15 human ovarian cancer xenografts. Mice
bearing well-established tumours were injected with cisplatin i.v. at a dose of
5 mg kg–1 every week ´ 2. The r value was calculated by linear regression
analysis.Topoisomerase IIa mRNA was detectable in all xenografts.
Expression levels varied between 0.73 in Ov.He xenografts and
2.66 in Ov.Ri(C) xenografts. The resistant xenografts FKo and
Ov.Gr expressed relatively low levels of topoisomerase IIa
mRNA. H134 tumours, however, contained moderate levels of
topoisomerase IIa mRNA. There was no relation between topoiso-
merase IIa expression and sensitivity to doxorubicin (r = 0.14).
Cell-cycle distribution
G1, S and G2/M phases of the xenografts were identified by flow
cytometric determination of cellular DNA content after propidium
iodide staining. Particular attention was paid to the S-phase frac-
tion, as in breast cancer patients a high fraction of cells in the S- or
S+G2-phase has been shown to predict for drug response
(Remvikos et al, 1989; Spyratos et al, 1992; Chevillard et al,
1996). The S-phase fraction varied between 2.4% and 39.4% in the
different xenografts (Table 3). A relatively low S-phase fraction
was found in the resistant xenograft Ov.Gr xenograft. FKo and
H134 tumours contained a high number of cells in S-phase.
Overall, there was a clear relation between the S-phase fraction
and the sensitivity to cisplatin (r = 0.66) (Figure 2), while this was
not the case for cyclophosphamide and doxorubicin (r = 0.31 and
0.34, respectively).
DISCUSSION
Drug resistance in general remains a barrier to the successful treat-
ment of solid tumours. Most research has been dedicated towards
the role of multi-drug-resistance (MDR) expressed by Pgp,
including measures to overcome MDR. Tumour heterogeneity in
the expression of MDR features may be a reason for the disap-
pointing results obtained in the treatment of solid tumours with
modulators of Pgp (Pinedo and Giaccone, 1995). The negative
data can also be due to the drug interaction between MDR modula-
tors and anti-cancer agents resulting in increased toxicity. Another
misleading factor is the misunderstood or overvalued role ascribed
to MDR from results obtained in vitro. A limitation of in vitro drug
resistance studies is the use of monolayer cultures of tumour cells,
which are known to be more vulnerable to drugs than the same
cells grown as solid tumours in vivo. This can be explained by
factors such as insufficient drug penetration, a reduced growth
fraction, or a decreased sensitivity mediated by cell–cell inter-
actions. In addition, drug resistance is very likely a multifactorial
phenomenon. Therefore, we determined a number of resistance
features in a large panel of human ovarian cancer xenografts that
was characterized earlier for drug sensitivity.
Several groups have shown that human tumour xenografts are
useful for drug screening and predictive for clinical drug response
(Boven et al, 1992; Langdon et al, 1994). In the panel of 15 human
ovarian cancer xenografts we have demonstrated that the efficacy
of cisplatin, cyclophosphamide and doxorubicin predicted for the
response rates of these drugs described in ovarian cancer patients
(Neijt et al, 1984). Briefly, by applying a cut-off growth inhibition
of > 75% it was shown that 40% of the xenografts responded to
cisplatin, which was close to the 48% reported in patients. For
cyclophosphamide the respective values were 27% and 40% and
for doxorubicin 20% and 35%. In this respect, we consider our
panel of human ovarian cancer xenografts of value to detect a
possible relation between the efficacy of anti-cancer agents and
drug resistance features. Moreover, host stroma contents are
limited in xenograft tissue which offers a better basis for tumour
tissue analysis than human tumour tissue invaded by thick layers
of stromal cells.
In none of the ovarian cancer xenografts could MDR1 expres-
sion be measured using the RNase protection assay, while expres-
sion of MDR1 was clearly detectable in the positive controls. In
general, the frequency and intensity of MDR1 expression or the
presence of Pgp in samples of ovarian cancer is low. In untreated
patient’s samples the expression rates for Pgp, determined by
immunohistochemistry, were 17%, 16% and 7% (Rubin et al,
1990; Izquierdo et al, 1995; Arts et al, 1999). In Northern blot
analysis MDR1 expression was undetectable in untreated patient’s
samples, while only 6% of samples of treated patients were
positive (Bourhis et al, 1989). The percentage of positive MDR1
expression increased to 81% (Noonan et al, 1990) and 36%
(Kavallaris et al, 1996) with the more sensitive polymerase chain
reaction (PCR). In our xenografts the expression levels of MDR1
were too low to detect with the RNase protection assay, which is in
agreement with Bourhis et al (1989). Whether low quantities of
MDR1, detectable only with PCR, are clinically meaningful is
questionable.
No relation could be established between MDR1 mRNA expres-
sion levels or the amount of MRP1 protein and the sensitivity to
doxorubicin or cisplatin. For cisplatin, this finding is consistent
with the inability of the MRP1 gene to confer resistance against
this drug, as has been demonstrated in transfection experiments
(Cole et al, 1994). In ovarian cancer patients MRP1 expression
failed to affect response to chemotherapy or disease-free survival
(lzquierdo et al, 1995; Kavallaris et al, 1996; Arts et al, 1999). It
has been shown that the GS-X pump is able to transport cisplatin
conjugated to glutathione out of the cell (Ishikawa and Ali-Osman,
1993). Although MRP1 appeared to be functionally related to the
GS-X pump, there are conflicting results on whether MRP1 plays
a role in platinum resistance. The precise role of MRP1 in clinical
drug resistance and, more specifically, in transporting glutathione-
drug conjugates out of the cell has yet to be delineated.
The drug-resistant and partly responsive human ovarian cancer
xenografts contained moderate to high levels of LRP mRNA and
LRP protein, and a weak, inverse relationship with the sensitivity
to cisplatin and cyclophosphamide (r = –0.44 and –0.45, respec-
tively), but not in the case of doxorubicin. In 61 unselected cancer
cell lines, it has been described that LRP expression was associ-
ated with relative resistance not only against carboplatin and
cisplatin, but also against melphalan and doxorubicin (Izquierdo
et al, 1996). This finding for both MDR and non-MDR drugs
supports the coexistence of different resistance mechanisms. In 57
patients with advanced ovarian cancer stage III/IV analysed by
Izquierdo et al (1995), LRP expression levels appeared to be an
independent prognostic factor of poor response to chemotherapy
and for shorter progression-free and overall survival. Of interest,
LRP expression was also associated with an inferior response to
induction chemotherapy in acute myeloid leukaemia (List et al,
1996), as well as to conventional dose melphalan in multiple
myeloma (Raaijmakers et al, 1998). In contrast, in a recent study in
115 patients with ovarian cancer stages I–IV, LRP expression was
more frequently observed in patients with early stage, lower grade,
and smaller residual tumour lesions (Arts et al, 1999), known to be
favourable prognostic factors in this type of disease. In that study,
LRP did not appear to be an independent prognostic factor for
Ovarian cancer xenografts and determinants for response 925
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able patients. Arts et al (1999) have speculated that the apparent
difference between patient populations in their study and that of
Izquierdo et al (1995) are responsible for the conflicting results.
Topoisomerase IIa mRNA levels varied 3.5-fold among the
human ovarian cancer xenografts and were not related to the sensi-
tivity to doxorubicin. Inter-tumour variability of the topoisomerase
IIa mRNA level and activity of the enzyme has been described in
ovarian cancer samples of patients (Van der Zee et al, 1991;
Cornarotti et al, 1996). Both groups have indicated a reduction in
topoisomerase IIa expression/activity after cisplatin-based
therapy, but the clinical utility of this determinant as an indicator
of drug resistance has been questioned. In addition, Hamaguchi et
al (1993) have shown that cross-resistance against doxorubicin in
cisplatin-resistant ovarian cancer cell lines was not due to alter-
ations in topoisomerase II mRNA levels, but merely the result of
an increased amount of glutathione.
Most studies on the predictive value of the cell-cycle distribu-
tion for the efficacy of chemotherapy have been carried out in
patients with breast cancer. A significant correlation has been
observed between the S-phase fraction and the response to
multiple anticancer agents given as neoadjuvant treatment before
surgery of the breast (Remvikos et al, 1989; Spyratos et al, 1992;
Chevillard et al, 1996). One study in soft tissue sarcoma patients
supported this finding, where seven out of 10 patients with S-
phase fractions > 6% showed a response to preoperative doxoru-
bicin and cisplatin. In contrast, only three of 12 soft tissue sarcoma
patients with a lower S-phase fraction responded to treatment
(Schmidt et al, 1993). In agreement with these data, the S-phase
fraction in our human ovarian cancer xenografts showed a relation
with the sensitivity to cisplatin (r = 0.66).
Multiple drug-resistance features may account for drug resis-
tance in vivo, while single mechanisms have mostly been
described in selected cell lines in vitro. The contribution of each
individual drug-resistance feature to the response observed in a
patient is still unclear. Clinically, cellular determinants of influ-
ence on the response rate are also difficult to define due to treat-
ment with multiple agents. Our panel of 15 human ovarian cancer
xenografts resembles both clinical histological subtypes and
chemosensitivity of ovarian cancer. In agreement with the
results obtained in patient’s samples, we could barely establish a
relationship between individual drug-resistance features and drug
response, in the case of single agents in our panel of 15 human
ovarian cancer xenografts. Other cellular features may be involved
in the complex phenotype of drug resistance in general, such as
DNA repair mechanisms contributing to resistance against alkyl-
ating agents, or variations in the apoptotic pathway causing a poor
drug response. Moreover, we recently observed that the degree of
tumour vascularization is of influence on the growth inhibition
induced by cisplatin (Duyndam et al, 2000). In vitro findings
should be tested in an appropriate human tumour system in vivo,
such as a panel of human tumour xenografts, to determine the
prognostic relevance of drug resistance features for cancer treat-
ment in the clinic.
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